ArticleLiver cancer2020
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
4 registry-linked trialsAbstract read
In one paragraph
Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 502 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
502citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With Pegylated Interferon Alfa-2b in Patients With Advanced-Stage Hepatocellular Carcinoma
Efficacy and Safety of Hepatic Artery Infusion Chemotherapy in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Progressed or Are Intolerant to Systemic Therapy
Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With S-adenosyl-methionine in Patients With Advanced-Stage Hepatocellular Carcinoma
Phase I/II Study of Anti-PD-1/PD-L1 Antibodies Combined With Anti-VEGF Antibody Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
Who cites it
502 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Narrow-margin hepatectomy combined with external beam radiotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Quantitative literature analysis on efficacy and safety of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma.BMC gastroenterology · 2025Pooled it
- A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.BMC gastroenterology · 2025Pooled it
- The research perspectives and frontiers on radiotherapy for hepatocellular carcinoma: a bibliometric analysis and systematic review.Frontiers in oncology · 2025Pooled it
- The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Diagnostic accuracy of methylatedFrontiers in endocrinology · 2025Pooled it
- Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.Signal transduction and targeted therapy · 2026Trial
- Trial
- Trial
- Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.BMC cancer · 2025Trial
- Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.Signal transduction and targeted therapy · 2024Trial
- Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial.Nature communications · 2024Trial
- Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial.Nature communications · 2024Trial
- Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.Scientific reports · 2024Trial
- Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204).Hepatology (Baltimore, Md.) · 2026Article
- Cell-free DNA methylation markers in the diagnosis of hepatitis B virus-related- hepatocellular carcinoma: a review.Molecular biology reports · 2026Review
- The relationship between mutations in reverse transcriptase region of hepatitis B virus and progression of liver disease.Virus genes · 2026Article
442 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
78 authors.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Huichuan SunLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenming CongDepartment of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jianhua WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Weiping ZhouThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Ping BieInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Lianxin LiuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Tianfu WenDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Guohong HanDepartment of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Maoqiang WangDepartment of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Ruibao LiuDepartment of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China.
Ligong LuDepartment of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhengang RenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Minshan ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhaochong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ping LiangDepartment of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Changhong LiangDepartment of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Min ChenEditorial Department of Chinese Journal of Digestive Surgery, Chongqing, China.
Fuhua YanDepartment of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Wenping WangDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingping YunDepartment of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, China.
Dingfang CaiDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Yongjun ChenDepartment of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenwu ChengDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuqun ChengThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Chaoliu DaiDepartment of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Wenzhi GuoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Baojin HuaGraduate School, Beijing University of Chinese Medicine, Beijing, China.
Xiaowu HuangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Weidong JiaDepartment of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Yaming LiDepartment of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China.
Yexiong LiDepartment of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Oncology, Peking University International Hospital, Beijing, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoyue LvDepartment of General Surgery, The First Hospital of Jilin University, Jilin, China.
Yilei MaoDepartment of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Tao PengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Weixin RenDepartment of Interventional Radiology The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoming ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Wentao WangDepartment of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Xiaoying WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiming WangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Baocai XingDepartment of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Jianming XuDepartment of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Jiamei YangThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Jianyong YangDepartment of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yefa YangDepartment of Hepatic Surgery & Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Yunke YangDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Shenglong YeLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhengyu YinDepartment of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Hubing South Road, Xiamen, China.
Bixiang ZhangDepartment of Surgery, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Boheng ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Leida ZhangDepartment of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China.
Shuijun ZhangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
Ti ZhangDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yongfu ZhaoDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
Honggang ZhengDepartment of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jiye ZhuDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
Kangshun ZhuDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Rong LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yinghong ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yongsheng XiaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhi DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Gaojun TengDepartment of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Jianqiang CaiDepartment of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weilin WangDepartment of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xiujun CaiDepartment of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.
Qiang LiDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Feng ShenThe Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Shukui QinDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Jiahong DongDepartment of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. SUMMARY: Since the publication of KEY MESSAGES: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People's Republic of China in December 2019.
Indexed as
CancerCarcinomaChinaDiagnosisLiverTreatment
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04943679ClinicalTrials.gov
NCT04994236ClinicalTrials.gov
NCT05701553ClinicalTrials.gov
NCT06537908ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.